Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 2
2018 1
2019 2
2021 4
2022 7
2023 1
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Results by year

Filters applied: . Clear all
Page 1
Aberrant ATM signaling and homology-directed DNA repair as a vulnerability of p53-mutant GBM to AZD1390-mediated radiosensitization.
Chen J, Laverty DJ, Talele S, Bale A, Carlson BL, Porath KA, Bakken KK, Burgenske DM, Decker PA, Vaubel RA, Eckel-Passow JE, Bhargava R, Lou Z, Hamerlik P, Harley B, Elmquist WF, Nagel ZD, Gupta SK, Sarkaria JN. Chen J, et al. Among authors: burgenske dm. Sci Transl Med. 2024 Feb 14;16(734):eadj5962. doi: 10.1126/scitranslmed.adj5962. Epub 2024 Feb 14. Sci Transl Med. 2024. PMID: 38354228
WSD-0922, a novel brain-penetrant inhibitor of epidermal growth factor receptor, promotes survival in glioblastoma mouse models.
Conage-Pough JE, Stopka SA, Oh JH, Mladek AC, Burgenske DM, Regan MS, Baquer G, Decker PA, Carlson BL, Bakken KK, Zhang J, Liu L, Sun C, Mu Z, Zhong W, Tran NL, Elmquist WF, Agar NYR, Sarkaria JN, White FM. Conage-Pough JE, et al. Among authors: burgenske dm. Neurooncol Adv. 2023 May 27;5(1):vdad066. doi: 10.1093/noajnl/vdad066. eCollection 2023 Jan-Dec. Neurooncol Adv. 2023. PMID: 37324218 Free PMC article.
RBBP4-p300 axis modulates expression of genes essential for cell survival and is a potential target for therapy in glioblastoma.
Mladek AC, Yan H, Tian S, Decker PA, Burgenske DM, Bakken K, Hu Z, He L, Connors MA, Carlson BL, Wilson J, Bommi-Reddy A, Conery A, Eckel-Passow JE, Sarkaria JN, Kitange GJ. Mladek AC, et al. Among authors: burgenske dm. Neuro Oncol. 2022 Aug 1;24(8):1261-1272. doi: 10.1093/neuonc/noac051. Neuro Oncol. 2022. PMID: 35231103 Free PMC article.
Molecular profiling of long-term IDH-wildtype glioblastoma survivors.
Burgenske DM, Yang J, Decker PA, Kollmeyer TM, Kosel ML, Mladek AC, Caron AA, Vaubel RA, Gupta SK, Kitange GJ, Sicotte H, Youland RS, Remonde D, Voss JS, Fritcher EGB, Kolsky KL, Ida CM, Meyer FB, Lachance DH, Parney IJ, Kipp BR, Giannini C, Sulman EP, Jenkins RB, Eckel-Passow JE, Sarkaria JN. Burgenske DM, et al. Neuro Oncol. 2019 Nov 4;21(11):1458-1469. doi: 10.1093/neuonc/noz129. Neuro Oncol. 2019. PMID: 31346613 Free PMC article. Clinical Trial.
Multimodal platform for assessing drug distribution and response in clinical trials.
Lopez BGC, Kohale IN, Du Z, Korsunsky I, Abdelmoula WM, Dai Y, Stopka SA, Gaglia G, Randall EC, Regan MS, Basu SS, Clark AR, Marin BM, Mladek AC, Burgenske DM, Agar JN, Supko JG, Grossman SA, Nabors LB, Raychaudhuri S, Ligon KL, Wen PY, Alexander B, Lee EQ, Santagata S, Sarkaria J, White FM, Agar NYR. Lopez BGC, et al. Among authors: burgenske dm. Neuro Oncol. 2022 Jan 5;24(1):64-77. doi: 10.1093/neuonc/noab197. Neuro Oncol. 2022. PMID: 34383057 Free PMC article.
Overcoming differential tumor penetration of BRAF inhibitors using computationally guided combination therapy.
Ng TSC, Hu H, Kronister S, Lee C, Li R, Gerosa L, Stopka SA, Burgenske DM, Khurana I, Regan MS, Vallabhaneni S, Putta N, Scott E, Matvey D, Giobbie-Hurder A, Kohler RH, Sarkaria JN, Parangi S, Sorger PK, Agar NYR, Jacene HA, Sullivan RJ, Buchbinder E, Mikula H, Weissleder R, Miller MA. Ng TSC, et al. Among authors: burgenske dm. Sci Adv. 2022 Apr 29;8(17):eabl6339. doi: 10.1126/sciadv.abl6339. Epub 2022 Apr 29. Sci Adv. 2022. PMID: 35486732 Free PMC article.
Temozolomide Sensitizes MGMT-Deficient Tumor Cells to ATR Inhibitors.
Jackson CB, Noorbakhsh SI, Sundaram RK, Kalathil AN, Ganesa S, Jia L, Breslin H, Burgenske DM, Gilad O, Sarkaria JN, Bindra RS. Jackson CB, et al. Among authors: burgenske dm. Cancer Res. 2019 Sep 1;79(17):4331-4338. doi: 10.1158/0008-5472.CAN-18-3394. Epub 2019 Jul 4. Cancer Res. 2019. PMID: 31273061 Free PMC article.
20 results